1. Scrip

Cerecor licenses second CNS asset from Merck

 
• By Mandy Jackson

Cerecor acquired worldwide, exclusive rights to develop and commercialize the Merck & Co compound MK-0657 (now CERC-301) – a small molecule NMDA receptor subunit 2 (NR2B) antagonist – in all indications, including depression. It is the first oral drug in the well-populated class of drugs targeting the NMDA receptor and the first oral rapid-acting antidepressant.

Cerecor acquired worldwide, exclusive rights to develop and commercialize the Merck & Co compound MK-0657 (now CERC-301) – a small molecule NMDA receptor subunit 2 (NR2B) antagonist – in all indications, including depression. It is the first oral drug in the well-populated class of drugs targeting the NMDA receptor and the first oral rapid-acting antidepressant.

The news in a nutshell

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.